TrialStudy of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Trial details
- Registry ID
- NCT03703310
- Phase
- Phase 3
SLGL
Sol-Gel Technologies, Ltd.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)NCT03703310 | SLGL | Phase 3 | Completed | 2020-12-28Actual |
| A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCCNCT04155190 | SLGL | Phase 2 | Terminated | 2021-04-23Actual |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)NCT04308395 | SLGL | Phase 3 | Terminated | 2021-07-14Actual |
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeNCT06050122 | SLGL | Phase 3 | Completed | 2026-08-20Actual |
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Trial details
- Registry ID
- NCT04155190
- Phase
- Phase 2
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Trial details
- Registry ID
- NCT04308395
- Phase
- Phase 3
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Trial details
- Registry ID
- NCT06050122
- Phase
- Phase 3
Latest recorded trial changes
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
NCT06050122 · Sol-Gel Technologies, Ltd.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
140 participants (planned)
+ After
113 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Oct 2026
+ After
20 Aug 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
NCT06050122 · Sol-Gel Technologies, Ltd.
Primary completion date changed
− Before
Aug 2026
+ After
Oct 2026
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
NCT04155190 · Sol-Gel Technologies, Ltd.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Number of New Surgically Eligible BCCs (nSEBs)
+ After
Measure: Number of Participants With New Surgically Eligible Basal Cell Carcinomas (nSEBs)